Basiliximab (Simulect) is a chimeric mouse-human monoclonal antibody to the IL-2Rα receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. It is a Novartis Pharmaceuticals product and was approved by the Food and Drug Administration (FDA) in 1998.

It is given in two doses, the first within 2 hours of the start of the transplant operation and the second 4 days after the transplant. These saturate the receptors and prevent T cell activation and thus prevent formation of antibodies against the transplant.

Like the similar drug daclizumab, basiliximab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of opportunistic infections. In the United Kingdom, the National Institute for Health and Clinical Excellence has recommended its use be considered for all kidney transplant recipients.

More on [ Basiliximab ]

Basiliximab - Twitter Search

RT@Bio_Network Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regula.. ht.. http://bit.ly/5s7YoG
Swineheart (Scott Fahrenkrug) Tue, 01 Dec 2009 17:47:22 -0000
RT@Bio_Network Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regula.. ht.. http://bit.ly/5s7YoG
Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regula.. http://bit.ly/4BxpNa www.bio-network.org
Bio_Network (George Maine) Tue, 01 Dec 2009 17:03:26 -0000
Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regula.. http://bit.ly/4BxpNa www.bio-network.org
basiliximab #2: in-vivo activ8d t-cell depletion 2 prevent graft-vs_host disease after nonmyeloablative http://bit.ly/7uS25t
paidtrials (US Clinical Trials) Tue, 01 Dec 2009 17:02:35 -0000
basiliximab #2: in-vivo activ8d t-cell depletion 2 prevent graft-vs_host disease after nonmyeloablative http://bit.ly/7uS25t

Subscribe to Basiliximab RSS feed